Who is sponsoring NCT00253786?

NCT00253786 is sponsored by Okayama University.

What drugs are being tested in NCT00253786?

Interventions in NCT00253786: Intensive multifactorial therapy, Standard therapy.

What condition does NCT00253786 study?

NCT00253786 studies Type 2 Diabetes Mellitus, Diabetic Nephropathy.

Is NCT00253786 still recruiting?

NCT00253786 is currently completed. Last updated 23 July 2019.

Last reviewed 2019-07-23 · How we verify

NCT00253786

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study for the Effectiveness of Intensive Therapy Aiming at a Remission of Diabetic Nephropathy

Completed NA Last updated 23 July 2019

What this trial tests

NA trial testing Intensive multifactorial therapy in Type 2 Diabetes Mellitus in 312 participants. Completed in 27 November 2014.

Timeline

11 November 2005

Primary endpoint
27 November 2014

27 November 2014

Quick facts

Lead sponsor	Okayama University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	312
Start date	11 November 2005
Primary completion	27 November 2014
Estimated completion	27 November 2014
Sites	1 location across Japan

Drugs / interventions tested

Intensive multifactorial therapy
Standard therapy — full drug profile →

Conditions studied

Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →
Diabetic Nephropathy — all drugs for Diabetic Nephropathy →

Sponsor

Okayama University

Who can join

Adults 20 to 75, any sex, with Type 2 Diabetes Mellitus or Diabetic Nephropathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study for the effectiveness of intensive therapy aiming at the remission of diabetic nephropathy

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Treatments for Chronic Kidney Disease: A Systematic Literature Review of Randomized Controlled Trials.
Garcia Sanchez JJ, Thompson J, Scott DA, Evans R, et al · · 2022 · cited 26× · PMID 34881414 · DOI 10.1007/s12325-021-02006-z
Randomized trial of an intensified, multifactorial intervention in patients with advanced-stage diabetic kidney disease: Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan).
Shikata K, Haneda M, Ninomiya T, Koya D, et al · · 2021 · cited 20× · PMID 32597548 · DOI 10.1111/jdi.13339

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes Mellitus

Currently open trials in the same condition.

NCT07351058 — A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes · Phase 3 · recruiting
NCT07373938 — Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus · recruiting
NCT07433062 — A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With · Phase 1 · recruiting
NCT07276776 — An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes · NA · active not recruiting
NCT07232537 — An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic · recruiting

Other Okayama University trials

Trials by the same sponsor.

NCT05485766 — Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer · Phase 2 · recruiting
NCT03450200 — Effectiveness of Exercises in Patient With Diabetic Peripheral Neuropathy · NA · completed
NCT03440203 — Prevalence of Peripheral Neuropathy and Its Impact on Activities of Daily Living in Patients With Type 2 Diabetes · completed
NCT03129568 — Transcoronary Infusion of Cardiac Progenitor Cells in Pediatric Dilated Cardiomyopathy · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00253786 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Okayama University
Last refreshed: 23 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00253786.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing